Is Kamada (KMDA) Stock Undervalued Right Now?
Value Investing Strategy: The Zacks Rank system identifies winning stocks through earnings estimates and revisions, while value investing focuses on finding undervalued stocks using fundamental analysis and valuation metrics.
Kamada's Value Metrics: Kamada (KMDA) is highlighted as a strong value stock with a Zacks Rank #2 (Buy), a P/E ratio of 21.4 compared to its industry's average of 37.33, and favorable P/B and P/S ratios, indicating it may be undervalued in the market.
Trade with 70% Backtested Accuracy
Analyst Views on KMDA
About KMDA
About the author
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections
Trial Discontinuation: Kamada Ltd. has announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating significant efficacy in improving lung function.
Stock Impact: Following the announcement, Kamada's stock experienced a decline of 5.51%, reflecting bearish market sentiment.
Future Outlook: Despite the trial setback, Kamada's CEO expressed confidence in the company's growth prospects, reiterating revenue guidance for 2025 and projecting double-digit growth in revenues and profitability for 2026.
Business Development Focus: Kamada plans to leverage its strong cash position to pursue new business development opportunities while continuing to expand its commercial portfolio, which includes FDA-approved products and a growing biosimilar portfolio.
Kamada Discontinues AAT Trial After Futility Analysis, Reiterates 2025 Revenue Guidance of $178M-$182M
- Trial Discontinuation: Kamada announced the discontinuation of its inhaled AAT trial based on an independent Data and Safety Monitoring Board's interim futility analysis, indicating a low likelihood of achieving statistical significance in the primary endpoint, although no safety concerns were identified.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million, indicating confidence in maintaining strong performance despite the disappointing trial results.
- Future Growth Outlook: Kamada projects double-digit growth in revenues and profitability for 2026, driven by its six FDA-approved specialty plasma-derived products marketed in over 30 countries and an expanding biosimilar portfolio.
- Business Development Strategy: The company is focused on pursuing new business development opportunities to support long-term growth, leveraging its strong cash position and existing commercial infrastructure to drive future market expansion and product development.
Analyst Predicts Increase in Hubspot Stock, Along with Insights on McGraw Hill, UHS, and Other Stocks.
Report Overview: Recent reports from investment and research firms provide insights into analysts' perspectives on various companies.
Disclaimer: The views expressed in these reports do not reflect the opinions or recommendations of Barron’s.
Investment Services: Some report issuers may have existing or potential investment-banking relationships with the companies analyzed.
Purpose of Reports: The reports serve as a sampling of analyst thinking rather than definitive investment advice.
Kamada Forecasts $200M-$205M Revenue for 2026 with 13% Growth
- 2026 Financial Outlook: Kamada projects revenues of $200 million to $205 million for 2026, representing a 13% year-over-year increase based on the midpoint of 2025 guidance, highlighting the company's ongoing organic growth potential across its diverse product portfolio in the biopharmaceutical sector.
- Adjusted EBITDA Growth: The company anticipates adjusted EBITDA to reach $50 million to $53 million in 2026, reflecting a 23% increase from the midpoint of 2025, which signifies a substantial enhancement in profitability and boosts investor confidence.
- Strong Cash Position: Kamada expects to end 2025 with approximately $75 million in cash, ensuring financial flexibility for future investments and business expansions, thereby strengthening its competitive edge in global markets.
- Strategic Development Focus: The company will continue to prioritize new business development and M&A transactions to accelerate long-term profitable growth, a strategy that will enrich its marketed product portfolio and generate synergies with existing operations.
Kamada Secures Supply Tender Extension, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has been awarded an extension of its existing supply tender from Canadian Blood Services for four specialty plasma-derived products, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby securing its market position in Canada.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA of $40 million to $44 million, reflecting strong and consistent performance in the market.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by its robust commercial portfolio and expansion of its biosimilar offerings, indicating strong competitive positioning in future markets.
- Strategic Development: The company intends to pursue additional contracts in key strategic territories, leveraging its strong cash position and existing commercial infrastructure to drive long-term growth and enhance its international market presence.
Kamada Secures Supply Tender Extension from CBS, Ensuring $5-$7 Million Annual Sales
- Contract Extension: Kamada has secured an extension of its existing supply tender from Canadian Blood Services, ensuring annual sales of approximately $5-$7 million between Q2-26 and Q1-28, thereby reinforcing its leadership position in the Canadian market.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million and adjusted EBITDA guidance of $40 million to $44 million, reflecting strong confidence in future performance.
- Growth Outlook: Kamada projects double-digit growth in revenues and profitability in 2026, driven by a robust commercial portfolio and expansion of its biosimilar offerings, indicating significant commercial potential in international markets.
- Strategic Development: The company plans to enhance revenue growth through the expansion of normal source plasma sales and collection operations, showcasing its long-term growth strategy in the biopharmaceutical sector.
Kamada Halts Phase 3 Trial for Genetic Disorder, Reaffirms Future Projections
Trial Discontinuation: Kamada Ltd. has announced the discontinuation of its Phase 3 InnovAATe trial for Inhaled AAT aimed at treating Alpha-1 Antitrypsin Deficiency (AATD) due to low likelihood of demonstrating significant efficacy in improving lung function.
Stock Impact: Following the announcement, Kamada's stock experienced a decline of 5.51%, reflecting bearish market sentiment.
Future Outlook: Despite the trial setback, Kamada's CEO expressed confidence in the company's growth prospects, reiterating revenue guidance for 2025 and projecting double-digit growth in revenues and profitability for 2026.
Business Development Focus: Kamada plans to leverage its strong cash position to pursue new business development opportunities while continuing to expand its commercial portfolio, which includes FDA-approved products and a growing biosimilar portfolio.
Kamada Discontinues AAT Trial After Futility Analysis, Reiterates 2025 Revenue Guidance of $178M-$182M
- Trial Discontinuation: Kamada announced the discontinuation of its inhaled AAT trial based on an independent Data and Safety Monitoring Board's interim futility analysis, indicating a low likelihood of achieving statistical significance in the primary endpoint, although no safety concerns were identified.
- Revenue Guidance Reaffirmed: The company reiterated its full-year 2025 revenue guidance of $178 million to $182 million, indicating confidence in maintaining strong performance despite the disappointing trial results.
- Future Growth Outlook: Kamada projects double-digit growth in revenues and profitability for 2026, driven by its six FDA-approved specialty plasma-derived products marketed in over 30 countries and an expanding biosimilar portfolio.
- Business Development Strategy: The company is focused on pursuing new business development opportunities to support long-term growth, leveraging its strong cash position and existing commercial infrastructure to drive future market expansion and product development.
